Enicostemma littorale (Mamejwa)
Enicostemma littorale Blume
Last reviewed by the Diabec Editorial Team.
Also known as: Mamejwa, Mamejavo, Mamejava, Chhota Chirayata, Indian whitehead gentian
Key Facts: Enicostemma littorale
- Scientific name: Enicostemma littorale Blume
- Common names: Mamejwa, Mamejavo, Mamejava, Chhota Chirayata, Indian whitehead gentian
- Plant family: Gentianaceae
- Origin: India, Sri Lanka, tropical Africa
- Key compounds: Swertiamarin, gentiopicroside, swertisin, gentianine, flavonoids
- Parts used: Whole plant (aerial parts)
- Published studies: a small body of papers on the plant, summarised in pharmacology reviews (PMID 34188450; PMID 29623834); human data is very limited
- Diabec dosage: Included as one of the six standardised Ayurvedic botanicals in each Diabec capsule
- Quality: Manufactured in an AYUSH-GMP certified facility; each capsule delivers a standardised botanical extract.
What Is Enicostemma littorale?
Enicostemma littorale (Enicostemma littorale Blume) is a small, bitter perennial herb in the gentian family, Gentianaceae. It grows in coastal and dry regions across India, Sri Lanka and parts of tropical Africa. In India it is known as Mamejwa and has a long history as a bitter tonic in Ayurvedic and folk traditions. The whole plant, mainly the aerial parts, is used. Researchers have examined its compounds, principally swertiamarin, largely in laboratory and animal models of glucose metabolism; human evidence is very limited (reviewed in PMID 34188450). It is one of six botanicals in the Diabec food supplement.
The heritage: the bitter tonic called Mamejwa
In the folk and Ayurvedic traditions of western India, the small bitter herb known as Mamejwa (also written Mamejavo or Mamejava) was valued as a bitter tonic and a remedy in everyday household practice. Healers traditionally used the whole plant, brewed or powdered, and its pronounced bitterness was, as with many gentian-family herbs, regarded as a sign of its usefulness. Much of this reputation rests on regional folk use rather than the large classical compendia, and it should be read as cultural tradition rather than proven medical effect. Modern researchers have since begun cataloguing the plant's compounds, with swertiamarin the most studied.
Framing reflects regional Indian folk and Ayurvedic usage of Enicostemma littorale (Mamejwa); it describes traditional practice and is not a verbatim quotation from any single text.The Key Active Compounds
The compounds in Enicostemma littorale have mostly been characterised in laboratory work. The table below summarises the most studied, their proposed role, and a representative reference. These are descriptions of the plant's chemistry, not claims about Diabec.
| Compound | Proposed role | Key study (PMID) |
|---|---|---|
| Swertiamarin | A secoiridoid glycoside and the plant's principal bitter constituent; the most-studied compound in preclinical glucose-metabolism models. | PMID 23840254 |
| Gentiopicroside | An iridoid glycoside characteristic of gentian-family plants, studied alongside swertiamarin in chemical and pharmacology reviews. | Reviewed in PMID 29623834 |
| Swertisin, gentianine and flavonoids | Minor constituents of the plant, associated with antioxidant activity in laboratory studies. | Reviewed in PMID 34188450 |
How Enicostemma has been studied in the body
The proposed mechanisms below are preclinical only, observed in isolated-compound or animal studies. They have not been confirmed in humans:
- 1Gene-expression changes in liver and fat tissue. Isolated swertiamarin modulated hepatic and adipose gene expression linked to PPAR-gamma in NIDDM rats. This is an isolated-compound animal finding, not a human result (Patel et al., PMID 23840254).
- 2Changes in glucose, insulin sensitivity and lipids. Aqueous whole-plant extract was linked to changes in fasting glucose, insulin sensitivity and lipid levels in chemically-induced diabetic rats. These are preclinical findings only (Murali et al., PMID 12065151; Vishwakarma et al., PMID 20358863).
- 3Antioxidant and hepatoprotective activity. Swertiamarin showed antioxidant and liver-protective effects in a rat model using the related species Enicostemma axillare, again a preclinical observation (PMID 20420896).
Evidence for Enicostemma littorale in glucose metabolism is predominantly preclinical (cell and rodent models) plus traditional use; human data is very limited - essentially one small early clinical study (2004) - so no firm conclusions about effects in people can be drawn.
What the Research Has Found
The research summaries below are for informational purposes only and do not constitute medical advice. Diabec is a food supplement, not a medicine. Consult your healthcare provider before use.
| Study | Type | Year | Finding | PMID |
|---|---|---|---|---|
| Upadhyay & Goyal | Human (small clinical, T2DM) | 2004 | An early small study reported glucose-related changes; small and old, so not confirmatory. | 15103671 |
| Patel et al. | Animal mechanism (NIDDM rats) | 2013 | Swertiamarin modulated hepatic and adipose gene expression linked to PPAR-gamma. | 23840254 |
| Murali et al. | Animal (NIDDM rats) | 2002 | Chronic extract was linked to changes in glucose, insulin and lipids. | 12065151 |
| Vishwakarma et al. | Animal (STZ type-1 rats) | 2010 | Aqueous extract reduced fasting glucose, glucose AUC, cholesterol and triglycerides. | 20358863 |
| Maroo et al. | Animal (alloxan rats) | 2003 | Dose-dependent glucose-lowering reported in the model. | 12725576 |
| Muhamad Fadzil et al. | Review | 2021 | Comprehensive review of swertiamarin chemistry and pharmacology. | 34188450 |
Side effects and precautions
Human safety data for Enicostemma littorale is limited. Most of what is known comes from its long traditional use and from rodent studies, where no adverse effects were reported at the doses tested in chronic animal protocols. As with any supplement, there are considerations to keep in mind.
Important - Please Read Before Use
- Limited human safety data - Most safety information comes from traditional use and rodent studies, in which no adverse effects were reported at the doses tested during chronic animal protocols. Robust human safety data is lacking.
- May interact with blood-sugar medications - There is a theoretical risk of additive blood-sugar lowering with insulin, metformin or sulfonylureas. Anyone taking diabetes medication should consult their healthcare provider and monitor their blood sugar closely.
- Pregnancy and breastfeeding - There is insufficient data on use during pregnancy or breastfeeding. It is best avoided in these groups unless a qualified healthcare professional advises otherwise; seek medical advice first.
- Possible mild digestive effects - As a bitter botanical, it may cause mild, transient gastrointestinal discomfort in some people, particularly at higher amounts or when first starting supplementation.
- Always consult your healthcare provider - Before starting any new supplement regimen, especially if you have existing health conditions or take prescription medications.
Frequently Asked Questions
What is Enicostemma littorale (Mamejwa)?
Enicostemma littorale, known in India as Mamejwa, is a small bitter herb in the gentian family (Gentianaceae). The whole plant has long been used as a bitter tonic in Ayurvedic and folk traditions across India. Diabec is a food supplement, not a medicine.
What compounds are found in Enicostemma?
The most studied is swertiamarin, a secoiridoid glycoside and the plant's principal bitter constituent. Gentiopicroside, swertisin, gentianine and various flavonoids are also present. These compounds have mainly been examined in laboratory and animal studies, not in large human trials.
What does the research on Enicostemma actually show?
Most research on Enicostemma littorale is preclinical, carried out in cell and rodent models, alongside its traditional use. Human data is very limited, essentially one small early clinical study from 2004. Because of this, no firm conclusions about effects in people can be drawn.
Is Enicostemma safe, and can it affect my medications?
Human safety data is limited, drawn mainly from traditional use and rodent studies, where no adverse effects were reported at tested doses. There is a theoretical risk of additive blood-sugar lowering with insulin, metformin or sulfonylureas. Consult your healthcare provider and monitor your blood sugar.
Can I take Enicostemma during pregnancy or breastfeeding?
There is insufficient data on the use of Enicostemma littorale during pregnancy or breastfeeding. Because safety has not been established in these groups, it is best avoided unless a qualified healthcare professional advises otherwise. Always seek medical advice before use if you are pregnant or breastfeeding.
Who should avoid Enicostemma?
People who are pregnant or breastfeeding should avoid it pending advice. Anyone taking blood-sugar-lowering medication should only use it under medical supervision. As a bitter botanical, it may cause mild, transient digestive discomfort in some people. Speak with your healthcare provider before starting any new supplement.
How does Enicostemma fit into Diabec?
Enicostemma is included as one of the six standardised Ayurvedic botanicals in each Diabec capsule, combined with five other herbs such as Gymnema, Bitter Melon, Fenugreek, Jamun and Neem. Diabec is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent any disease.
How long does it take to see results with Enicostemma?
Because reliable human data is very limited, we cannot promise any particular outcome or timeframe. Individual experiences vary with diet, lifestyle, form and dose. Any botanical supplement is best taken consistently alongside a balanced diet and a healthy lifestyle, not as a substitute for either.
How Diabec Uses Enicostemma
Enicostemma littorale, the bitter herb known in India as Mamejwa, has a long history in Ayurvedic and folk practice. Diabec carries that traditional heritage into capsule form. Enicostemma is combined with five other Ayurvedic herbs as part of the six-herb Diabec formula, with each botanical included at a standardised level for batch-to-batch consistency. Diabec is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent any disease.
A traditional Ayurvedic herb
Used as a bitter tonic in Indian folk and Ayurvedic tradition, brought into a simple daily capsule
Standardised botanical
Included at a standardised level so each batch is consistent capsule to capsule
6-Herb Combined Formula
Combined with five other Ayurvedic herbs as part of the six-herb Diabec formula
Related Ingredients
Discover the five other herbs that work alongside Enicostemma in the Diabec formula. Swipe to explore.
View credentials
This article is maintained by the Diabec Editorial Team against a documented editorial standard. We do not present individual practitioner credentials unless a named, registered professional has reviewed the page. Our review basis is:
- Peer-reviewed sourcing. Every health-related statement is referenced to peer-reviewed, PubMed-indexed literature. This page cites 8 such references, each linked to its PubMed record.
- Honest evidence summary. We state plainly that the evidence for Enicostemma littorale is predominantly preclinical, with human data limited to one small early clinical study.
- Quality of manufacture. Our Enicostemma is produced at a facility certified to AYUSH Good Manufacturing Practices (GMP).
- Publisher. Published by NIBARTECH LTD, a company registered in England & Wales (no. 15283998).
- Review cadence. Content is dated and re-reviewed on a scheduled basis. Last reviewed June 2026.
This page is for education and does not constitute medical advice. Speak with a qualified healthcare professional before changing any treatment.